報告綁定套組:雙特異性抗體的T細胞免疫療法及CAR & TCR改變T細胞
2 Reports Bundle: T-Cell Immunotherapy by Bispecific Antibodies and CAR & TCR Engineered T-Cells (Two Reports released in 2016)
|出版商||La Merie Publishing||商品編碼||368816|
|報告綁定套組:雙特異性抗體的T細胞免疫療法及CAR & TCR改變T細胞 2 Reports Bundle: T-Cell Immunotherapy by Bispecific Antibodies and CAR & TCR Engineered T-Cells (Two Reports released in 2016)|
|出版日期: 2016年09月01日||內容資訊: 英文||
Immunotherapy of cancer with direct or indirect use of T-cells is one of the most exciting fields of cancer research. Direct T-cell therapy implies the ex vivo engineering of autologous or allogeneic T-cells for tumor targeting by chimeric antigen receptors (CAR) or T-cell receptors (TCR). Indirect T-cell therapy leverages the capability of tumor-targeted bispecific antibodies to redirect T-cells to the tumor. This report package includes two full reports covering both aspects of T-cell immunotherapy of cancer.
The original reports were published in May and August 2016, respectively: